2B4 co-engagement promotes serial degranulation and killing by human NK cells
Activation of Natural Killer (NK) cells depends on the stimulation of a broad range of receptors. Here we use murine NIH3T3 target cells expressing defined human NK cell ligands to stimulate different aspects of NK cell activity and identify how distinct ligand-receptor interactions regulate different aspects of NK cell activation. B7H6, MICA, and CD20-bound obinutuzumab engaging NKp30, NKG2D, or…
Two different approaches to activating immune cells known as Natural Killer (NK) cells have been discovered by researchers. These cells are essential for the body's defense against infections and cancers. The study utilized murine NIH3T3 target cells, which express specific human NK cell ligands, to stimulate various aspects of NK cell activity.
By binding to receptors B7H6, MICA, and CD20, a substance called obinutuzumab was found to effectively boost the activity of NK cells that are pre-stimulated. When this substance was combined with CD48, it further increased the production of degranulation and cytokine secretion by NK cells. Additionally, when the receptor PVR interacting with DNAM-1 was stimulated in conjunction with B7H6, it led to beneficial effects on NK cells.
However, the activation of activating NK cell receptors varied depending on which ligand was used. CD16 and NKp46, two receptors in particular, showed indications of being downregulated based on the extent of NK cell activation triggered by other receptors. The results of this systematic analysis reveal the intricate relationship between different activating NK cell receptors, and offer potential strategies for tailoring NK cell reactivities for therapeutic purposes.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.